ExpreS2ion will participate in key industry and investor events
Hørsholm, Denmark, April 7, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the World Vaccine Congress (April 18-21), a Q&A session covering the 2022 Rights Issue (April 25), Økonomisk Ugebrev Life Science Investor Conference (April 27), PEGS Summit (May 2-6), and the ESMO Breast Cancer Meeting (May 3-5).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.
World Vaccine Congress, April 18-21
Washington, D.C., USA
Meet in-person with ExpreS2ion’s CMO, Mattis Flyvholm Ranthe at the largest, most established meeting dedicated to vaccines. More information and registration can be found on the World Vaccine Congress website.
2022 Rights Issue Q&A hosted by H.C. Andersen Capital, April 25 at 11:00 CET
Virtual
ExpreS2ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the 2022 Rights Issue and answer investor’s questions about how to participate. More information and registration can be found on the H.C. Andersen Capital events website closer to the webcast.
Økonomisk Ugebrev Life Science Investor Conference, April 27 at 15:50-16:20 CET
Copenhagen, Denmark
See the company presentation by our CEO Bent U. Frandsen at this investor event. It is possible to attend the meeting by reserving a seat on the event website.
PEGS Summit, May 2-6
Boston, MA, USA
Meet virtually with ExpreS2ion’s VP of R&D and Technology, Max Søgaard, at the leading international meeting for the biotherapeutics community. More information and registration can be found on the PEGS Summit website.
European Society for Medical Oncology (ESMO) Breast Cancer Meeting, May 3-5
Berlin, Germany and Virtual
Meet with ExpreS2ion’s CMO, Mattis Flyvholm Ranthe, and VP of Preclinical Development, Mette Thorn, at 2022 ESMO Breast Cancer meeting. More information and registration can be found on the ESMO website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.